New addition to GORE® CARDIOFORM Occluder family is designed to treat larger atrial septal defects by adapting to the patient’s anatomy for a permanent and safe closure
Sep 26, 2017
W. L. Gore & Associates (Gore) today announced a favorable ruling involving the GORE® HELEX® Septal Occluder.
Aug 5, 2013
Gore REDUCE Clinical Study demonstrated 77 percent relative reduction in recurrent ischemic stroke when PFO closure was combined with antiplatelet therapy, compared to antiplatelet therapy alone
Apr 3, 2018
Completion of follow -up paves way for REDUCE Clinical Study data submission to FDA for PFO indication
Mar 30, 2017